KR20150092282A - 신규한 피리딘 유도체 - Google Patents
신규한 피리딘 유도체 Download PDFInfo
- Publication number
- KR20150092282A KR20150092282A KR1020157017889A KR20157017889A KR20150092282A KR 20150092282 A KR20150092282 A KR 20150092282A KR 1020157017889 A KR1020157017889 A KR 1020157017889A KR 20157017889 A KR20157017889 A KR 20157017889A KR 20150092282 A KR20150092282 A KR 20150092282A
- Authority
- KR
- South Korea
- Prior art keywords
- pyridine
- cyclopropylmethoxy
- carboxylic acid
- amide
- cyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- HVZUVBAZMQRYFI-UHFFFAOYSA-N CN(C)C(CC1(COC1)N)=O Chemical compound CN(C)C(CC1(COC1)N)=O HVZUVBAZMQRYFI-UHFFFAOYSA-N 0.000 description 1
- TYIUIRJZAOKTNM-UHFFFAOYSA-N CN(C)C(CC1(COC1)NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O Chemical compound CN(C)C(CC1(COC1)NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O TYIUIRJZAOKTNM-UHFFFAOYSA-N 0.000 description 1
- GUBZREBIEPAYBB-UHFFFAOYSA-N CNC(CC1(COC1)NC(c1nc(OCC2CC2)c(C2CC2)cc1)=O)=O Chemical compound CNC(CC1(COC1)NC(c1nc(OCC2CC2)c(C2CC2)cc1)=O)=O GUBZREBIEPAYBB-UHFFFAOYSA-N 0.000 description 1
- HWEBJLDVJFLAGV-UHFFFAOYSA-N COC(CC(C1)(CNC1=O)NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O Chemical compound COC(CC(C1)(CNC1=O)NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O HWEBJLDVJFLAGV-UHFFFAOYSA-N 0.000 description 1
- HUYVZVINZREGFV-UHFFFAOYSA-N COC(CC1(CSC1)NC(c1nc(OCC2CC2)c(C2(COC2)F)cc1)=O)=O Chemical compound COC(CC1(CSC1)NC(c1nc(OCC2CC2)c(C2(COC2)F)cc1)=O)=O HUYVZVINZREGFV-UHFFFAOYSA-N 0.000 description 1
- PODTYUCVUPUSNR-UHFFFAOYSA-N COC(c1nc(Cl)c(C(F)(F)F)cc1)=O Chemical compound COC(c1nc(Cl)c(C(F)(F)F)cc1)=O PODTYUCVUPUSNR-UHFFFAOYSA-N 0.000 description 1
- NYVIPUKWWICLDA-UHFFFAOYSA-N NC(CC(C(F)(F)F)NC(c1nc(OCC2CC2)c(C2CC2)cc1)=O)=O Chemical compound NC(CC(C(F)(F)F)NC(c1nc(OCC2CC2)c(C2CC2)cc1)=O)=O NYVIPUKWWICLDA-UHFFFAOYSA-N 0.000 description 1
- BELHZNFDLAQKHV-UHFFFAOYSA-N NC(CC(C1)(CS1(=O)=O)NC(c1cccc(-c(cc2Cl)ccc2F)n1)=O)=O Chemical compound NC(CC(C1)(CS1(=O)=O)NC(c1cccc(-c(cc2Cl)ccc2F)n1)=O)=O BELHZNFDLAQKHV-UHFFFAOYSA-N 0.000 description 1
- OMXHNXHSWWODTI-UHFFFAOYSA-N NC(CC(C1)(CS1(=O)=O)NC(c1nc(OCC2CC2)c(C2CC2)cc1)=O)=O Chemical compound NC(CC(C1)(CS1(=O)=O)NC(c1nc(OCC2CC2)c(C2CC2)cc1)=O)=O OMXHNXHSWWODTI-UHFFFAOYSA-N 0.000 description 1
- RJFPQEQTAJLPSJ-UHFFFAOYSA-N NC(CC(C1CCCCC1)NC(c1nc(OCC2CC2)c(C2CC2)cc1)=O)=O Chemical compound NC(CC(C1CCCCC1)NC(c1nc(OCC2CC2)c(C2CC2)cc1)=O)=O RJFPQEQTAJLPSJ-UHFFFAOYSA-N 0.000 description 1
- WEBIPWRCFXHPRG-UHFFFAOYSA-N NC(CC1(CCNCC1)NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O Chemical compound NC(CC1(CCNCC1)NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O WEBIPWRCFXHPRG-UHFFFAOYSA-N 0.000 description 1
- KGYKANRITXXAGL-UHFFFAOYSA-N NC(CC1(CNCC1)NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O Chemical compound NC(CC1(CNCC1)NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O KGYKANRITXXAGL-UHFFFAOYSA-N 0.000 description 1
- GDMPFDPVDVOJSG-UHFFFAOYSA-N NC(CC1(CSC1)NC(c1nc(OCC2CC2)c(C2(CCC2)O)cc1)=O)=O Chemical compound NC(CC1(CSC1)NC(c1nc(OCC2CC2)c(C2(CCC2)O)cc1)=O)=O GDMPFDPVDVOJSG-UHFFFAOYSA-N 0.000 description 1
- WZYWZJBPRBZKFR-KGLIPLIRSA-N NC([C@H](CCCC1)[C@H]1NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O Chemical compound NC([C@H](CCCC1)[C@H]1NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O WZYWZJBPRBZKFR-KGLIPLIRSA-N 0.000 description 1
- HSACMDWEGJKSRG-UHFFFAOYSA-N OC(CC(C1)(CN1C(OCc1ccccc1)=O)NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O Chemical compound OC(CC(C1)(CN1C(OCc1ccccc1)=O)NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O HSACMDWEGJKSRG-UHFFFAOYSA-N 0.000 description 1
- RLGXIAABJYNWSI-UHFFFAOYSA-N OC(CC(CCc1ccccc1)NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O Chemical compound OC(CC(CCc1ccccc1)NC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O)=O RLGXIAABJYNWSI-UHFFFAOYSA-N 0.000 description 1
- XBIFXIZBKZGCDC-UHFFFAOYSA-N OC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O Chemical compound OC(c(cc1)nc(OCC2CC2)c1N(C1)CC1(F)F)=O XBIFXIZBKZGCDC-UHFFFAOYSA-N 0.000 description 1
- JPKWMNNAPKYWNH-UHFFFAOYSA-N OC(c1ccc(C2CC2)c(OCC2CC2)n1)=O Chemical compound OC(c1ccc(C2CC2)c(OCC2CC2)n1)=O JPKWMNNAPKYWNH-UHFFFAOYSA-N 0.000 description 1
- KJQYBXFQKXGNFX-UHFFFAOYSA-N OC(c1nc(Cl)c(C2(COC2)F)cc1)=O Chemical compound OC(c1nc(Cl)c(C2(COC2)F)cc1)=O KJQYBXFQKXGNFX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12196022.3 | 2012-12-07 | ||
| EP12196022 | 2012-12-07 | ||
| PCT/EP2013/075225 WO2014086705A1 (en) | 2012-12-07 | 2013-12-02 | Novel pyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150092282A true KR20150092282A (ko) | 2015-08-12 |
Family
ID=47290804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157017889A Withdrawn KR20150092282A (ko) | 2012-12-07 | 2013-12-02 | 신규한 피리딘 유도체 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9522886B2 (https=) |
| EP (2) | EP3357918A1 (https=) |
| JP (1) | JP6426618B2 (https=) |
| KR (1) | KR20150092282A (https=) |
| CN (2) | CN104837831B (https=) |
| AR (1) | AR093843A1 (https=) |
| AU (2) | AU2013354278B2 (https=) |
| BR (1) | BR112015012919A2 (https=) |
| CA (1) | CA2890100A1 (https=) |
| CL (1) | CL2015001536A1 (https=) |
| CO (1) | CO7350620A2 (https=) |
| CR (1) | CR20150250A (https=) |
| DK (1) | DK2928881T3 (https=) |
| EA (1) | EA026669B1 (https=) |
| ES (1) | ES2668690T3 (https=) |
| HR (1) | HRP20180672T1 (https=) |
| HU (1) | HUE036911T2 (https=) |
| IL (1) | IL239075B (https=) |
| LT (1) | LT2928881T (https=) |
| MA (1) | MA38239A1 (https=) |
| MX (1) | MX2015007155A (https=) |
| NO (1) | NO2928881T3 (https=) |
| PE (1) | PE20151025A1 (https=) |
| PH (1) | PH12015501083B1 (https=) |
| PL (1) | PL2928881T3 (https=) |
| PT (1) | PT2928881T (https=) |
| RS (1) | RS57143B1 (https=) |
| SG (2) | SG10201800170YA (https=) |
| SI (1) | SI2928881T1 (https=) |
| TW (1) | TWI600645B (https=) |
| UA (1) | UA114656C2 (https=) |
| WO (1) | WO2014086705A1 (https=) |
| ZA (1) | ZA201503969B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014224784B2 (en) | 2013-03-07 | 2018-03-08 | F. Hoffmann-La Roche Ag | Novel pyrazol derivatives |
| CN105121436B (zh) | 2013-03-26 | 2018-07-27 | 豪夫迈·罗氏有限公司 | 新的吡啶衍生物 |
| AU2014261585B2 (en) | 2013-05-02 | 2018-03-08 | F. Hoffmann-La Roche Ag | Purine derivatives as CB2 receptor agonists |
| WO2014177527A1 (en) | 2013-05-02 | 2014-11-06 | F. Hoffmann-La Roche Ag | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists |
| JP6441356B2 (ja) | 2013-09-06 | 2018-12-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規トリアゾロ［４，５−ｄ］ピリミジン誘導体 |
| CN111170938A (zh) * | 2014-04-04 | 2020-05-19 | 豪夫迈·罗氏有限公司 | 作为大麻素受体激动剂的5,6-双取代的吡啶-2-甲酰胺 |
| WO2015190564A1 (ja) * | 2014-06-13 | 2015-12-17 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| EP3386951B1 (en) * | 2015-12-09 | 2020-02-26 | H. Hoffnabb-La Roche Ag | Phenyl derivatives as cannabinoid receptor 2 agonists |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| AR112199A1 (es) | 2017-06-20 | 2019-10-02 | Hoffmann La Roche | Derivados de piridina como agonistas inversos del receptor cannabinoide 2 |
| JP2021521228A (ja) * | 2018-04-18 | 2021-08-26 | ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ | Ｄ−グルカロ−６，３−ラクトンモノエステル及びその製造方法 |
| JP7456948B2 (ja) | 2018-06-27 | 2024-03-27 | エフ． ホフマン－ラ ロシュ アーゲー | 放射性標識カンナビノイド受容体２リガンド |
| EP3814337B1 (en) * | 2018-06-27 | 2025-05-14 | F. Hoffmann-La Roche AG | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
| CN112119068A (zh) * | 2018-06-27 | 2020-12-22 | 豪夫迈·罗氏有限公司 | 作为大麻素受体2的抑制剂的新型氮杂环丁烷-取代的吡啶和吡嗪化合物 |
| PE20210368A1 (es) | 2018-06-27 | 2021-02-26 | Eth Zuerich | Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2 |
| CN114502538A (zh) * | 2019-09-30 | 2022-05-13 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的经取代的3,4-二氢喹唑啉 |
| JP2023541601A (ja) | 2020-09-10 | 2023-10-03 | プレシリックス・ナームローゼ・ベンノートシヤープ | Ｆａｐに対する抗体フラグメント |
| MX2023012365A (es) * | 2021-04-19 | 2023-11-27 | Chemocentryx Inc | Azetidinil-acetamidas como inhibidores de cxcr7. |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| CA3251753A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | PRE-TARGETTING |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008040649A2 (en) * | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | Pyrazine-2-carboxamide derivatives as cb2 receptor modulators |
| WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| AR085013A1 (es) * | 2011-01-26 | 2013-08-07 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
-
2013
- 2013-12-02 SG SG10201800170YA patent/SG10201800170YA/en unknown
- 2013-12-02 EA EA201591064A patent/EA026669B1/ru not_active IP Right Cessation
- 2013-12-02 SI SI201331023T patent/SI2928881T1/en unknown
- 2013-12-02 US US14/648,431 patent/US9522886B2/en not_active Expired - Fee Related
- 2013-12-02 RS RS20180493A patent/RS57143B1/sr unknown
- 2013-12-02 CN CN201380063475.9A patent/CN104837831B/zh not_active Expired - Fee Related
- 2013-12-02 EP EP18154216.8A patent/EP3357918A1/en not_active Withdrawn
- 2013-12-02 EP EP13799520.5A patent/EP2928881B1/en not_active Not-in-force
- 2013-12-02 MA MA38239A patent/MA38239A1/fr unknown
- 2013-12-02 WO PCT/EP2013/075225 patent/WO2014086705A1/en not_active Ceased
- 2013-12-02 SG SG11201504416XA patent/SG11201504416XA/en unknown
- 2013-12-02 UA UAA201506688A patent/UA114656C2/uk unknown
- 2013-12-02 PT PT137995205T patent/PT2928881T/pt unknown
- 2013-12-02 NO NO13799520A patent/NO2928881T3/no unknown
- 2013-12-02 HU HUE13799520A patent/HUE036911T2/hu unknown
- 2013-12-02 CN CN201710932324.2A patent/CN107674061A/zh active Pending
- 2013-12-02 LT LTEP13799520.5T patent/LT2928881T/lt unknown
- 2013-12-02 AU AU2013354278A patent/AU2013354278B2/en not_active Ceased
- 2013-12-02 KR KR1020157017889A patent/KR20150092282A/ko not_active Withdrawn
- 2013-12-02 PE PE2015000744A patent/PE20151025A1/es not_active Application Discontinuation
- 2013-12-02 ES ES13799520.5T patent/ES2668690T3/es active Active
- 2013-12-02 CA CA2890100A patent/CA2890100A1/en not_active Abandoned
- 2013-12-02 BR BR112015012919A patent/BR112015012919A2/pt not_active Application Discontinuation
- 2013-12-02 HR HRP20180672TT patent/HRP20180672T1/hr unknown
- 2013-12-02 MX MX2015007155A patent/MX2015007155A/es unknown
- 2013-12-02 PL PL13799520T patent/PL2928881T3/pl unknown
- 2013-12-02 JP JP2015545757A patent/JP6426618B2/ja not_active Expired - Fee Related
- 2013-12-02 DK DK13799520.5T patent/DK2928881T3/en active
- 2013-12-06 AR ARP130104545A patent/AR093843A1/es unknown
- 2013-12-06 TW TW102144952A patent/TWI600645B/zh not_active IP Right Cessation
-
2015
- 2015-04-29 CO CO15097806A patent/CO7350620A2/es unknown
- 2015-05-12 CR CR20150250A patent/CR20150250A/es unknown
- 2015-05-15 PH PH12015501083A patent/PH12015501083B1/en unknown
- 2015-05-28 IL IL239075A patent/IL239075B/en not_active IP Right Cessation
- 2015-06-03 ZA ZA2015/03969A patent/ZA201503969B/en unknown
- 2015-06-05 CL CL2015001536A patent/CL2015001536A1/es unknown
-
2017
- 2017-12-20 AU AU2017279648A patent/AU2017279648A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20150092282A (ko) | 신규한 피리딘 유도체 | |
| AU2017200801B2 (en) | Pyridin- 2 -amides useful as CB2 agonists | |
| EP1591443B1 (en) | Pyrazole derivative | |
| EP2928882B1 (en) | Pyrazine derivatives as cb2 receptor agonists | |
| TWI617551B (zh) | 新穎吡啶衍生物 | |
| JP6654574B2 (ja) | Ｃｂ２アゴニストとして有用なピリジン−２−アミド | |
| WO2020002270A1 (en) | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists | |
| HK1208031B (en) | Novel pyridine derivatives | |
| TW201336837A (zh) | 新穎氮雜環丁烷衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20150703 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |